中国医学专家在肺癌围术期免疫治疗研究方面取得了新的突破。据研究结果显示，国产原研创新免疫药特瑞普利单抗联合化疗，可显著延长非小细胞肺癌患者的无事件生存期，为众多局部进展期患者开辟出一条“逃生通道”。
无事件生存期是指患者在诊断为肺癌后，经过一定的治疗后，没有发生与癌症相关的死亡事件的时间。这一指标的延长，意味着患者的生存期得到了显著的延长，生活质量也得到了改善。
这项研究由中国医学专家进行，他们通过对大量肺癌患者的临床数据进行分析，发现国产原研创新免疫药特瑞普利单抗联合化疗的疗效显著。这一发现对于肺癌患者来说无疑是一大福音，为他们提供了更多的治疗选择。
据悉，这项研究的结果已经在国际知名的医学期刊上发表。中国医学专家表示，他们将继续深入研究，以期为肺癌患者提供更多的治疗策略。
这项研究的取得，标志着中国在肺癌免疫治疗领域的研究水平达到了国际先进水平，为中国肺癌患者带来了新的希望。
英语如下：
Title: Innovative Local-made Immune Drugs + Chemotherapy: New Life for Lung Cancer Patients
Keywords: 1. Innovative local-made immune drugs
Content: Chinese medical experts have made a new breakthrough in the research of immune therapy during the perioperative period of lung cancer. According to the research results, the combination of locally-made innovative immunotherapy drug, Tropicalresonance (Tropiva), and chemotherapy can significantly extend the event-free survival period of patients with non-small cell lung cancer (NSCLC), opening up a “escape channel” for many patients with locally advanced stage cancer.
Event-free survival period refers to the time from the diagnosis of lung cancer to a certain extent after treatment, without any death events related to cancer. The extension of this indicator means that the survival period of patients has been significantly extended, and their quality of life has also been improved.
This study was conducted by Chinese medical experts who analyzed a large number of clinical data of lung cancer patients and found that the effect of the combination of locally-made innovative immunotherapy drug Tropiva and chemotherapy was significant. This discovery is undoubtedly a great blessing for lung cancer patients, providing them with more treatment options.
It is reported that the results of this study have been published in well-known international medical journals. Chinese medical experts said that they would continue to conduct in-depth research to provide more treatment strategies for lung cancer patients.
The achievements of this study mark that the research level of China in the field of lung cancer immune therapy has reached the international advanced level, bringing new hope to Chinese lung cancer patients.
【来源】http://www.chinanews.com/life/2024/01-17/10147905.shtml
Views: 1